venBio Partners — Full Portfolio

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)

Board seatRobert Adelman· per SEC Form D

Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more

Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation.

BiotechHealthtechVancouver, B.C., US

Anthony Clarke(Executive Officer)Richard Stewart(Director)Cindy Jacobs(Executive Officer, Director)Jaime Xinos(Executive Officer)John Bencich(Executive Officer, Director)

BoardBridget Martell(Director)

Co-investorsVivo CapitalFrazier Life Sciences

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)

Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementWestlake Village BioPartners+1 more

Cambridge, GB

Co-investors+ND Capital

ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.

BiotechHealthtech

Co-investorsage1Foresite CapitalLightstone Ventures

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos, Ph.d.(President and Treasurer)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)

Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxi+4 more

Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)Errik Anderson(Executive Officer, Director)Steve Tregay(Director)

Co-investorsBioBritF-Prime CapitalForesite CapitalOrbiMedVivo Capital

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.

BiotechHealthtechMedical DevicesNew Brunswick, US

Joaquin Duatoin

Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column Group

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)

Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+5 more

BiotechWaltham, US

John Pallies(Executive Officer)Arlene Morris(Executive Officer, Director)

BoardDennis Podlesak(Director)Ivor Royston(Director)Luke Evnin, Ph.D.(Director)Kim Kamdar, Ph.D(Director)

Co-investorsForesite CapitalPappas CapitalSofinnova Ventures

Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

BiotechHealthtechSouth San Francisco, US

Deepak Srivastava, M.D.(Scientific Founder)Eric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)Sheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)Eric Hyllengren(Chief Financial Officer)

Co-investorsGV (Google Ventures)The Column Group

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)

Co-investorsMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+7 more

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.

BiotechDigital HealthMedical DevicesRedwood City, US

Emmett Cunningham(Executive Officer, Director)Mark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)Oliver Stauch(Executive Officer)inOliver Boris Stauch(Executive Officer)Conrad Wang(Director)

Co-investorsFrazier Life SciencesHealthQuest CapitalvenBio Global Strategic

HealthtechNew York, US

Shawn Leland(Executive Officer, Director)Lori Hu(Director)Michael Caldwell(Director)

BoardSteven Elms(Executive Officer, Director, Promoter)

Board seatRichard Gaster· per SEC Form D · $65M raise · filed Nov 2020

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Board seatRichard Gaster· per SEC Form D

Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsSofinnova VenturesvenBio Global Strategic

HealthtechSouth San Francisco, US

Aaron Kantoff(Director)Mark Iwicki(Director)Graham Walmsley(Director)Jonathan Young(Executive Officer)Andrew Cheng(Executive Officer, Director)

Board seatAaron Royston· per SEC Form D · $45.5M raise · filed Dec 2018

Co-investorsAtlas Venture

BiotechDublin 2

Jason Lettman(Director)

Board seatJaume PonsCorey Goodman· per SEC Form D · $36M raise · filed May 2015

NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.

Crestwood, US

Board seatRobert Adelman· per SEC Form D

Co-investorsEMBL VenturesEpidarex Capital

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)

Board seatCorey Goodman· per SEC Form D

Co-investorsAlpha Wave GlobalBioBritvenBio Global StrategicVivo Capital

HealthtechSeattle, US

John D. Hoekman(Executive Officer, Director)

BoardMichael Hite(Director)Stewart Parker(Director)

Board seatAaron Royston· per SEC Form D · $37.3M raise · filed Dec 2016

Co-investors5AM VenturesB Capital GroupvenBio Global StrategicWestlake Village BioPartners

San Francisco, US

Board seatAaron Royston· per SEC Form D · $160.4M raise · filed Jun 2024

Co-investorsSofinnova Ventures

BiotechMenlo Park, US

Steven L. Basta(Executive Officer, Director)John Creecy(Director)Scott Whitcup(Director)Ted Ebel(Director)Ketan Patel(Director)David Collier(Director)

Board seatAaron Royston· per SEC Form D · $50.5M raise · filed Jul 2017

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in

Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016

Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+2 more

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

Board seatAaron Royston· per SEC Form D

Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossoverVersant VenturesVivo Capital+1 more

BiotechSan Francisco, US

Curt Bradshaw(Executive Officer, Director, Promoter)Frank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)Louis Tartaglia(Mr. Tartaglia is a Manager of the Issuer.)

BoardCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)

Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015

Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.

BiotechHealthtechBurlingame, US

Board seatJaume PonsCorey Goodman· per SEC Form D

Co-investorsLightstone VenturesMRL Ventures FundMatrix Partners ChinavenBio Global Strategic

BiotechSan Diego, US

Jingrong Jean Cui(Executive Officer, Director)Jingrong Cui(Executive Officer, Director)Yishan Li(Executive Officer, Director)

BoardGeorge J. Lee(Director)Kenneth Fong(Director)Bihua Chen(Director)

Board seatRobert Adelman· per SEC Form D · $80M raise · filed Oct 2018

35Pharma is a biopharmaceutical company that designs and develops ligand traps targeting the Activin x GDF signaling pathway to treat pulmonary hypertension, heart failure, and obesity.

BiotechHealthtech

Co-investorsFrazier Life SciencesJanus Henderson InvestorsVivo Capital

AI & Machine LearningBiotechDigital HealthHealthtech

Co-investorsDecheng CapitalSamsara BioCapital

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas VentureForesite CapitalFrazier Life SciencesScion Life SciencesThe Innovation SpaceVersant Ventures

Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.

BiotechHealthtechBoston, US

Co-investorsAndera PartnersConnecticut Innovations

Co-investorsAvoro Capital AdvisorsEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta Ventures

Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.

BiotechHealthtechBoulder, US

Joey Azofeifa(Founder)inJoseph G. Azofeifa(Executive Officer, Director)Laura Norris(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)

BoardAmit Mehta(Director)

Co-investorsFifty YearsFundersClubTau VenturesY CombinatorBoxOne VenturesvenBio Global Strategic+1 more

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)

BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in

Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)Pfizer Venture Investments+1 more

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases.

BiotechHealthtechSan Diego, US

Jennifer Bush(Executive Officer)Yong-Jun Huh(Director)Thomas J. Farrell(Executive Officer)Yu-Kyeong Hwang(Director)Fred Aslan(Executive Officer, Director)Jason Litten(Executive Officer)

Co-investors5AM VenturesEcoR1 CapitalRA CapitalvenBio Global Strategic

BiotechSan Francisco, US

Matthew Patterson(Executive Officer, Director)

BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)Jonathan Leff(Director)Thomas Woiwode(Director)

Co-investorsAsset Management CompanyRA CapitalDeerfield Management CompanyOrbiMedVenrock

BiotechVictoria

Kurt von Emster(Director)Benjamin Rovinski(Director)Chris Kim(Director)Donald Wyatt(Director)Stephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)

Co-investorsLumira VenturesNew Enterprise Associates (NEA)

BiotechLa Jolla, US

Sepehr Sarshar(Director)David A. Stamler(Executive Officer)Andreas Sommer(Executive Officer)Pratik Shah(Director)Lawrence C. Fritz(Executive Officer, Director)

BoardDavid Collier(Director)

Co-investorsThomas, McNerney & Partners

Axent Biosciences develops cell therapies using engineered, fully synthetic biocompatible biomaterials that create protective environments for cells.

BiotechHealthtechNew Materials

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVOmega FundsvenBio Global Strategic+1 more

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)

Co-investorsAtlas VentureJanus Henderson InvestorsLAV

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesVida Ventures

Entact is a drug discovery company developing treatments for patients.

BiotechDeep TechWatertown, US

Victoria Richon(Executive Officer, Director, Promoter)Ruben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)

BoardAndrew Sinclair(Director)Anna French(Director)

Co-investorsvenBio Global Strategic

BiotechWoburn, US

David Lucchino(Executive Officer, Director)Christopher R. Loose(Executive Officer)

BoardRobert Langer(Director)Marc Kozin(Director)Marc Cohen(Director)Timothy Barberich(Director)

Co-investorsAlexandriaKendall Capital Partners

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more

HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories.

AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US

Ke Cheng(Founder/CEO)inLinh Hoang(Chief Executive Officer)Jerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)

Co-investorsVivo CapitalY Combinator

Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules.

BiotechHealthtechMedical Devices

Co-investorsCowles VenturesNorwest Venture Partners

Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.

AI & Machine LearningBiotechDeep TechChippendale, AU

TIMOTHY CRAVEN(Executive Officer, Director)TOBY PASSIOURA(Executive Officer, Director)Tim Craven(CEO)Toby Passioura(CSO)Glen McIntyre(COO)GLEN MCINTYRE(Executive Officer, Director)

Co-investorsCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalAxial VCvenBio Global Strategic

Lyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors.

BiotechHealthtech

Co-investorsARCH Venture PartnersForesite Capital8VCAxial VC

Co-investorsAlpha Wave GlobalSofinnova Ventures

South San Francisco, US

Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.

BiotechHealthtechWoburn, US

Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)

BoardDAVID ALLISON(Director)

Co-investors5AM VenturesOrbiMedSamsara BioCapitalVivo CapitalvenBio Global StrategicWestlake Village BioPartners

NFlection is a clinical-stage biopharmaceutical company developing topical first-in-class MEK inhibitors for RAS-mediated disorders.

BiotechMedical DevicesBoston, US

Co-investorsF-Prime CapitalvenBio Global Strategic

NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases.

BiotechHealthtech

Co-investorsNew Science VenturesYsios CapitalSofinnova Ventures

Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops late-stage rare disease drugs deprioritized by larger pharmaceutical companies.

BiotechHealthtech

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBain Capital Life SciencesForesite CapitalKurma Partners

Portage Biotech is a clinical-stage immuno-oncology company developing first-in-class cancer therapies that target checkpoint resistance pathways.

BiotechHealthtech

Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.

BiotechHealthtechTarrytown, US

Co-investorsRidgeback CapitalSanderling VenturesWireframe Ventures

Co-investorsBoutique Venture PartnersOUP (Osage University Partners)

Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.

BiotechLa Jolla, US

Jay Lichter(Director)Douglas Downs(Executive Officer)Floyd Romesberg(Director)Court Turner(Executive Officer, Director)

Co-investorsAvalon BioVenturesBoutique Venture PartnersCorrelation VenturesOUP (Osage University Partners)RA Capital

Teva Pharmaceuticals is a biopharmaceutical company that develops innovative medicines across therapeutic areas such as neuroscience and immunology, alongside a large generics and biosimilars business.

BiotechHealthtech

Co-investorsBlumberg Capital

San Diego, US

Mark S. Forman(Executive Officer)Matthew Moore(Executive Officer)John Nuss(Executive Officer)Jigar Choksey(Director)Martin Auster(Executive Officer)Christopher W. Krueger(Executive Officer)

Co-investorsNew Science VenturesThird Point VenturesSilverArc PrivatevenBio Global Strategic

Verona Pharma develops treatments for chronic lung conditions.

BiotechHealthtechLondon

Jan-Anders Karlsson(Executive Officer, Director)Peter Spargo(Executive Officer)Patrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)

Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more

Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.

BiotechCambridge, US

Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)

BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in

Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalForesite Capital

AI & Machine LearningBiotechHealthtech

Co-investorsAvoro Capital AdvisorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)